Abstract 592P
Background
Debate surrounds the surgical management of Goblet cell adenocarcinoma (GCA). However, right hemicolectomy (RHC) remains the standard surgical choice for GCA.
Methods
1154 and 867 patients with GCA were extracted from U.S. Surveillance, Epidemiology, and End Results (SEER) and National Cancer Registration and Analysis Service (NCRAS) databases respectively after excluding patients with missing data. Two clusters for each cohort were created using an unsupervised machine learning K-means model (cluster 0, cluster 1). Clustering was evaluated using silhouette (S), Davies Boulden (DB) and Caliniski Harabasz (CH) scores. Clusters were visualised using principal component analysis (PCA) and T-distributed stochastic neighbour embedding (T-SNE). SHapley Additive exPlanations (SHAP) identified clinical features that were the most useful in clustering. Kaplan Meier (KM) statistics and graphs were generated. Decision trees were developed to cluster individual patients in each of the two clusters.
Results
PCA and T-SNE visualisations showed distinct clusters with some overlap in both cohorts. SHAP revealed tumour size and stage as important variables for clustering in SEER, while age and stage were key variables in NCRAS. Clusters description and survival are shown in the table. The two clusters were statistically different in survival based on Cox regression, Log-rank test and KM statistics in both cohorts. Appendectomy and RHC showed similar survival rates across both cohorts and within each cluster of both cohorts. Table: 592P
Characteristics of clusters and 5-year survival rates
Characteristic | Clustrer 0Favourable survival | Cluster 1Unfavourable survival |
Median age, years (SEER) | 58 | 59 |
Male sex, % (SEER) | 48 | 54 |
Localised stage, % (SEER) | 64 | 33 |
Distant stage, % (SEER) | 3 | 19 |
Tumour size, median mm (SEER) | 14 | 50 |
5-year survival, % (95% CI) (SEER) | 85(82-88) | 72(59-72) |
Median age, years (NCRAS) | 48 | 68 |
Male sex, % (NCRAS) | 56 | 43 |
Localised stage, % (NCRAS) | 90 | 81 |
Distant stage, % (NCRAS) | 4 | 9 |
5-year survival, % (95% CI) (NCRAS) | 87(83-91) | 61(57-66) |
Conclusions
After categorising cases into two clusters using unsupervised machine learning, RHC and appendectomy demonstrated comparable survival rates among patients with GCA. Machine learning could facilitate clinicians in exploring the impact of various treatment approaches on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hampshire Hospitals NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
576P - Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Presenter: Jifang Gong
Session: Poster session 16
577P - Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Presenter: Eric Christenson
Session: Poster session 16
579P - Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
Presenter: Paolo Nuciforo
Session: Poster session 16
581P - mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Presenter: Marco Germani
Session: Poster session 16
582P - Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study
Presenter: debora basile
Session: Poster session 16
583P - COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
Presenter: Blanca García-Mico
Session: Poster session 16
584P - Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences
Presenter: Nerma Crnovrsanin
Session: Poster session 16
585P - Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Presenter: Norbert Marschner
Session: Poster session 16